Drug Profile
Spinosad - Eli Lilly and Company/ParaPRO
Alternative Names: LY-232105; Natroba; NatrOVA; PP-105; XDE-105Latest Information Update: 05 Aug 2021
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer ParaPRO
- Class Antiparasitics; Macrolides
- Mechanism of Action GABA receptor agonists; Nervous system stimulants; Nicotinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Pediculosis; Scabies
Most Recent Events
- 02 Aug 2021 Launched for Scabies (In adolescents, In children, In the elderly, In adults) in USA (Topical)
- 01 Jan 2021 Registered for Scabies (In adolescents, In children, In the elderly, In adults) in USA, in early 2021 (Topical)
- 03 Aug 2018 ParaPRO completes a phase III trial in Scabies (In adolescents, In adults, In children, In the elderly) in USA (NCT02485704)